Literature DB >> 7120045

Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression.

R D Toothaker, P G Welling.   

Abstract

The pharmacokinetics of hydrocortisone were examined following single intravenous doses of 5, 10, 20, and 40 mg hydrocortisone, as the sodium succinate salt, to healthy male volunteers. Endogenous hydrocortisone was suppressed by administration of 2 mg dexamethasone the night before hydrocortisone injection. Plasma samples obtained serially during 8 h after hydrocortisone injection were assayed by reverse-phase HPLC using a fixed wavelength (254 nm) ultraviolet detector. Initial concentrations of hydrocortisone in plasma were proportional to dose size. The subsequent decline in hydrocortisone concentrations was biphasic, and individual data sets were adequately described in terms of the pharmacokinetic two-compartment open model. Values of pharmacokinetic parameters were similar from the 5, 10, and 20 mg doses. Following the 40 mg dose, the overall elimination rate constant decreased, while the distribution volume, Vdss, and plasma clearance increased, in comparison with the values obtained from lower doses. Changes in the pharmacokinetics of hydrocortisone at high doses may be related to drug concentration-dependent changes in the binding of hydrocortisone to plasma proteins. Previously reported dose-dependent changes in some pharmacokinetic parameters following oral hydrocortisone are attributed to absorption rather than distribution or elimination effects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7120045     DOI: 10.1007/bf01062332

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  15 in total

1.  THE INFLUENCE OF PLASMA PROTEIN BINDING ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN NORMAL, HYPERTHYROID AND HYPOTHYROID SUBJECTS.

Authors:  W R BEISEL; V C DIRAIMONDO; P Y CHAO; J M ROSNER; P H FORSHAM
Journal:  Metabolism       Date:  1964-10       Impact factor: 8.694

2.  The physiological disposition and metabolic fate of hydrocortisone in man.

Authors:  R E PETERSON; J B WYNGAARDEN; S L GUERRA; B B BRODIE; J J BUNIM
Journal:  J Clin Invest       Date:  1955-12       Impact factor: 14.808

3.  Potentiation of adrenocortical response upon intermittent stimulation with corticotropin in normal subjects.

Authors:  J Kolanowski; M A Pizarro
Journal:  J Clin Endocrinol Metab       Date:  1975-09       Impact factor: 5.958

4.  Kinetic studies of cortisol and synthetic corticosteroids in man.

Authors:  P J Fell
Journal:  Clin Endocrinol (Oxf)       Date:  1972-01       Impact factor: 3.478

5.  Corticosteroid analysis in biological fluids by high-performance liquid chromatography.

Authors:  J Q Rose; W J Jusko
Journal:  J Chromatogr       Date:  1979-03-01

6.  Determination of plasma and urinary cortisol by high-performance liquid chromatography using fluorescence derivatization with dansyl hydrazine.

Authors:  T Kawasaki; M Maeda; A Tsuji
Journal:  J Chromatogr       Date:  1979-06-11

7.  Determination of cortisol in human plasma by reversed-phase high-performance liquid chromatography.

Authors:  N R Scott; P F Dixon
Journal:  J Chromatogr       Date:  1979-09-11

8.  Suppression of endogenous hydrocortisone with dexamethasone.

Authors:  T J Goehl; G M Sundaresan; J P Hunt; V K Prasad; R D Toothaker; P G Welling
Journal:  J Pharm Sci       Date:  1980-12       Impact factor: 3.534

9.  Quantitation of dexamethasone in biological fluids using high-performance liquid chromatography.

Authors:  S E Tsuei; J J Ashley; R G Moore; W G McBride
Journal:  J Chromatogr       Date:  1978-03-01

10.  Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma.

Authors:  F J Frey; B M Frey; L Z Benet
Journal:  Clin Chem       Date:  1979-11       Impact factor: 8.327

View more
  4 in total

1.  Dose-dependent pharmacokinetics of dexamethasone.

Authors:  D Loew; O Schuster; E H Graul
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 2.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 3.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults.

Authors:  Johanna Melin; Zinnia P Parra-Guillen; Niklas Hartung; Wilhelm Huisinga; Richard J Ross; Martin J Whitaker; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.